SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hallegua, D S
Right arrow Articles by Wallace, D J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hallegua, D S
Right arrow Articles by Wallace, D J
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Lupus
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

How accelerated atherosclerosis in SLE has changed our management of the disorder

D S Hallegua

Division of Rheumatology, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA, USA; 8737 Beverly Boulevard, Suite 203, Los Angeles, CA 90048, USA

D J Wallace

Division of Rheumatology, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA, USA

Basic science insights along with the assessment of risk factors so clearly documented by the Canadian and Hopkins cohorts in earlier papers of this special issue have clearly led to a change in the way rheumatologists manage SLE. This review will highlight specific ways it should alter our day to day treatment of lupus patients.

Key Words: coronary artery disease (CAD) • systemic lupus erythematosus (SLE) • corticosteroids (CS)

Lupus, Vol. 9, No. 3, 228-231 (2000)
DOI: 10.1191/096120300678828181
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
M. Soares, L Reis, J A. Papi, and C R. Cardoso
Rate, pattern and factors related to damage in Brazilian systemic lupus erythematosus patients
Lupus, October 1, 2003; 12(10): 788 - 794.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
V. M. Martinez-Taboada, M. J. Bartolome, M. D. Fernandez-Gonzalez, R. Blanco, V. Rodriguez-Valverde, and M. Lopez-Hoyos
Homocysteine levels in polymyalgia rheumatica and giant cell arteritis: influence of corticosteroid therapy
Rheumatology, September 1, 2003; 42(9): 1055 - 1061.
[Abstract] [Full Text] [PDF]


Advertisement